Abstract
The development of selective inhibitors for discrete anti-apoptotic BCL-2 family proteins implicated in pathologic cell survival remains a formidable but pressing challenge. Such precisely tailored compounds would serve as molecular probes and targeted therapies to study and treat human diseases driven by specific anti-apoptotic blockades. In particular, MCL-1 has emerged as a major resistance factor in human cancer. By screening a library of stabilized alpha-helix of BCL-2 domains (SAHBs), we determined that the MCL-1 BH3 helix is itself a potent and exclusive MCL-1 inhibitor. X-ray crystallography and mutagenesis studies defined key binding and specificity determinants, including the capacity to harness the hydrocarbon staple to optimize affinity while preserving selectivity. MCL-1 SAHB directly targets MCL-1, neutralizes its inhibitory interaction with pro-apoptotic BAK and sensitizes cancer cells to caspase-dependent apoptosis. By leveraging nature's solution to ligand selectivity, we generated an MCL-1–specific agent that defines the structural and functional features of targeted MCL-1 inhibition.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Tsujimoto, Y., Cossman, J., Jaffe, E. & Croce, C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228, 1440–1443 (1985).
Danial, N.N. & Korsmeyer, S.J. Cell death: critical control points. Cell 116, 205–219 (2004).
Sattler, M. et al. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275, 983–986 (1997).
Muchmore, S.W. et al. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381, 335–341 (1996).
Chen, L. et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol. Cell 17, 393–403 (2005).
Zhai, D., Jin, C., Huang, Z., Satterthwait, A.C. & Reed, J.C. Differential regulation of Bax and Bak by anti-apoptotic Bcl-2 family proteins Bcl-B and Mcl-1. J. Biol. Chem. 283, 9580–9586 (2008).
Kitada, S. et al. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 46, 4259–4264 (2003).
Nguyen, M. et al. Small molecule obatoclax (GX15–070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 104, 19512–19517 (2007).
Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677–681 (2005).
Tse, C. et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 68, 3421–3428 (2008).
Wang, G. et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J. Med. Chem. 49, 6139–6142 (2006).
Konopleva, M. et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10, 375–388 (2006).
van Delft, M.F. et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10, 389–399 (2006).
Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899–905 (2010).
Zhang, B., Gojo, I. & Fenton, R.G. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99, 1885–1893 (2002).
Boisvert-Adamo, K., Longmate, W., Abel, E.V. & Aplin, A.E. Mcl-1 is required for melanoma cell resistance to anoikis. Mol. Cancer Res. 7, 549–556 (2009).
Ding, Q. et al. Myeloid Cell Leukemia-1 inversely correlates with glycogen synthase kinase-3β activity and associates with poor prognosis in human breast cancer. Cancer Res. 67, 4564–4571 (2007).
Lin, X. et al. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26, 3972–3979 (2007).
Meng, X.W. et al. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43–9006)-induced TRAIL sensitization. J. Biol. Chem. 282, 29831–29846 (2007).
Taniai, M. et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res. 64, 3517–3524 (2004).
Danial, N.N. et al. Dual role of proapoptotic BAD in insulin secretion and beta cell survival. Nat. Med. 14, 144–153 (2008).
Walensky, L.D. et al. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 305, 1466–1470 (2004).
Gavathiotis, E. et al. BAX activation is initiated at a novel interaction site. Nature 455, 1076–1081 (2008).
Walensky, L.D. et al. A stapled BID BH3 helix directly binds and activates BAX. Mol. Cell 24, 199–210 (2006).
Schafmeister, C., Po, J. & Verdine, G. An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122, 5891–5892 (2000).
Blackwell, H.E. et al. Ring-closing metathesis of olefinic peptides: design, synthesis, and structural characterization of macrocyclic helical peptides. J. Org. Chem. 66, 5291–5302 (2001).
Boersma, M.D., Sadowsky, J.D., Tomita, Y.A. & Gellman, S.H. Hydrophile scanning as a complement to alanine scanning for exploring and manipulating protein-protein recognition: application to the Bim BH3 domain. Protein Sci. 17, 1232–1240 (2008).
Day, C.L. et al. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J. Mol. Biol. 380, 958–971 (2008).
Letai, A. et al. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183–192 (2002).
Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M. & Cravatt, B.F. Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. USA 101, 10000–10005 (2004).
Clohessy, J.G., Zhuang, J., de Boer, J., Gil-Gomez, G. & Brady, H.J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem. 281, 5750–5759 (2006).
Han, J., Goldstein, L.A., Gastman, B.R. & Rabinowich, H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 281, 10153–10163 (2006).
Akgul, C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 66, 1326–1336 (2009).
Warr, M.R. & Shore, G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr. Mol. Med. 8, 138–147 (2008).
Bae, J., Leo, C.P., Hsu, S.Y. & Hsueh, A.J. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J. Biol. Chem. 275, 25255–25261 (2000).
Kim, S.H., Ricci, M.S. & El-Deiry, W.S. Mcl-1: a gateway to TRAIL sensitization. Cancer Res. 68, 2062–2064 (2008).
Ricci, M.S. et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12, 66–80 (2007).
Bird, G.H., Bernal, F., Pitter, K. & Walensky, L.D. Chapter 22 Synthesis and biophysical characterization of Stabilized Alpha-helices of BCL-2 Domains. Methods Enzymol. 446, 369–386 (2008).
Pitter, K., Bernal, F., LaBelle, J.L. & Walensky, L.D. Chapter 23 Dissection of the BCL-2 family signaling network with Stabilized Alpha-Helices of BCL-2 Domains. Methods Enzymol. 446, 387–408 (2008).
Otwinowski, Z. & Minor, W. Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
Storoni, L.C., McCoy, A.J. & Read, R.J. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D Biol. Crystallogr. 60, 432–438 (2004).
Adams, P.D. et al. PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr. D Biol. Crystallogr. 58, 1948–1954 (2002).
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 (2004).
Lynch, V.M., Tanaka, T., Fishpaugh, J.R., Martin, S.F. & Davis, B.E. Structure of (+/−)-(1R*,4S*,6S*)-1-benzyloxy-4,8,11,11-tetramethyl-6-phenylthio-bicyclo[5.3.1]undec-7-en-3-one. Acta Crystallogr. C 46, 1351–1353 (1990).
Davis, I.W. et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 35, W375–W383 (2007).
Acknowledgements
We thank E. Smith (Dana-Farber Cancer Institute) for editorial and graphics support, R.A. Grant (Massachussets Institute of Technology) for input on the crystallography experiments, X-ray data collection and structural analysis, and C.H. Yun and M.J. Eck (Dana-Farber Cancer Institute) for assistance in generating the hydrocarbon staple parameter file used in the structural refinement. This work was supported by US National Institutes of Health grant 5P01CA92625 and a Burroughs Wellcome Career Award in the Biomedical Sciences to L.D.W., a Ruth L. Kirschstein National Research Service Award 1F31CA144566 to M.L.S. and US National Institutes of Health award 5RO1GM084181 to A.E.K. X-ray diffraction data were acquired at the Advanced Photon Source on the Northeastern Collaborative Access Team beamlines, which are supported by award RR-15301 from the National Center for Research Resources at the US National Institutes of Health. Use of the Advanced Photon Source is supported by the US Department of Energy, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.
Author information
Authors and Affiliations
Contributions
M.L.S. and L.D.W. designed, synthesized and characterized SAHB compounds for biochemical, structural and cellular analyses. M.L.S. performed the X-ray crystallography experiments with E.F. in the laboratory of A.E.K., who supervised the structural analyses. M.L.S. conducted all biochemical and cellular analyses, with guidance from L.D.W. L.D.W. and M.L.S. wrote the manuscript, which was reviewed and edited by E.F. and A.E.K.
Corresponding author
Ethics declarations
Competing interests
L.W. is a scientific advisor board member and consultant for Aileron Therapeutics.
Supplementary information
Supplementary Text and Figures
Supplementary Methods, Supplementary Tables 1–3 and Supplementary Figures 1–6 (PDF 704 kb)
Rights and permissions
About this article
Cite this article
Stewart, M., Fire, E., Keating, A. et al. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol 6, 595–601 (2010). https://doi.org/10.1038/nchembio.391
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.391
This article is cited by
-
A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells
Molecular Medicine (2023)
-
BH3-mimetics: recent developments in cancer therapy
Journal of Experimental & Clinical Cancer Research (2021)
-
Targeting MCL-1 in cancer: current status and perspectives
Journal of Hematology & Oncology (2021)
-
Targeting apoptosis in cancer therapy
Nature Reviews Clinical Oncology (2020)
-
Peptidomimetics: A Synthetic Tool for Inhibiting Protein–Protein Interactions in Cancer
International Journal of Peptide Research and Therapeutics (2020)